Sanofi reports business EPS of 1.78 euros for the first three months of 2024, down 17.6% on a reported basis and 7.4% at constant exchange rates, reflecting in particular an 11.8% rise in R&D expenditure.

At nearly 10.5 billion euros, sales rose by 2.4% (+6.7% at CER), with growth 'driven by the continued strong performance of Dupixent and new launches', according to CEO Paul Hudson.

The French healthcare giant expects its 2024 business EPS to fall to the low single-digit range at CCT 'taking into account the expected increase in the tax rate, barring unforeseen major adverse events'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.